{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T04:30:17Z","timestamp":1793939417665,"version":"4.8.0"},"reference-count":41,"publisher":"BMJ","issue":"4","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Neurol Neurosurg Psychiatry"],"accepted":{"date-parts":[[2024,8,6]]},"published-print":{"date-parts":[[2025,4]]},"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Neuromyelitis optica spectrum disorder (NMOSD) can be categorised into aquaporin-4 antibody (AQP4-IgG) NMOSD or seronegative NMOSD. While our knowledge of AQP4-IgG NMOSD has evolved significantly in the past decade, seronegative NMOSD remains less understood. This study aimed to evaluate the predictors of relapses and treatment responses in AQP4-IgG NMOSD and seronegative NMOSD.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This was a multicentre, international, retrospective cohort study using the MSBase registry. Recurrent relapse risk was assessed using an Andersen-Gill model and risk of first relapse was evaluated using a Cox proportional hazards model. Covariates that putatively influence relapse risk included demographic factors, clinical characteristics and immunosuppressive therapies; the latter was assessed as a time-varying covariate.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 398 patients (246 AQP4-IgG NMOSD and 152 seronegative NMOSD) were included. The AQP4-IgG NMOSD and seronegative NMOSD patients did not significantly differ by age at disease onset, ethnicity or annualised relapse rate. Both low-efficacy and high-efficacy immunosuppressive therapies were associated with significant reductions in recurrent relapse risk, with notably greater protection conferred by high-efficacy therapies in both AQP4-IgG NMOSD (HR 0.27, 95% CI 0.15 to 0.49, p&lt;0.001) and seronegative NMOSD (HR 0.21, 95% CI 0.08 to 0.51, p&lt;0.001). Longer disease duration (HR 0.97, 95% CI 0.95 to 0.99, p&lt;0.001) and male sex (HR 0.52, 95% CI 0.34 to 0.84, p=0.007) were additional protective variables in reducing the recurrent relapse risk for the AQP4-IgG NMOSD group.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Although further studies are needed to improve our understanding of seronegative NMOSD, our findings underscore the importance of aggressive treatment with high-efficacy immunotherapies in both NMOSD subtypes, regardless of serostatus.<\/jats:p><\/jats:sec>","DOI":"10.1136\/jnnp-2024-334090","type":"journal-article","created":{"date-parts":[[2024,9,4]],"date-time":"2024-09-04T17:21:48Z","timestamp":1725470508000},"page":"361-369","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":19,"title":["Predictors of relapse risk and treatment response in AQP4-IgG positive and seronegative NMOSD: A multicentre study"],"prefix":"10.1136","volume":"96","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4751-2102","authenticated-orcid":false,"given":"Pakeeran","family":"Siriratnam","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Sanfilippo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4278-7003","authenticated-orcid":false,"given":"Anneke","family":"van der Walt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7294-9723","authenticated-orcid":false,"given":"Sifat","family":"Sharmin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi Chao","family":"Foong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei Zhen","family":"Yeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3951-7501","authenticated-orcid":false,"given":"Chao","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3198-6063","authenticated-orcid":false,"given":"Samia Joseph","family":"Khoury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tunde","family":"Csepany","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Willekens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masoud","family":"Etemadifar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serkan","family":"Ozakbas,","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petra","family":"Nytrova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayse","family":"Altintas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdullah","family":"Al-Asmi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bassem","family":"Yamout","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guy","family":"Laureys","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Patti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magdolna","family":"Simo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Surcinelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0321-7155","authenticated-orcid":false,"given":"Matteo","family":"Foschi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2704-8517","authenticated-orcid":false,"given":"Pamela A","family":"McCombe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raed","family":"Alroughani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Luis","family":"S\u00e1nchez-Menoyo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Recai","family":"Turkoglu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aysun","family":"Soysal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeanette","family":"Lechner Scott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3778-1376","authenticated-orcid":false,"given":"Tomas","family":"Kalincik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helmut","family":"Butzkueven","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3942-4340","authenticated-orcid":false,"given":"Vilija","family":"Jokubaitis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0980-3750","authenticated-orcid":false,"given":"Saif","family":"Huda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mastura","family":"Monif","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2024,9,4]]},"reference":[{"key":"2025032404000925000_96.4.361.1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(07)70216-8"},{"key":"2025032404000925000_96.4.361.2","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.65.7.913"},{"key":"2025032404000925000_96.4.361.3","doi-asserted-by":"publisher","DOI":"10.7861\/clinmedicine.19-2-169"},{"key":"2025032404000925000_96.4.361.4","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000001729"},{"key":"2025032404000925000_96.4.361.5","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2020.102451"},{"key":"2025032404000925000_96.4.361.6","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000626","article-title":"Classifying the antibody-negative NMO syndromes: clinical, imaging, and metabolomic modeling","volume":"6","author":"Yeo","year":"2019","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"2025032404000925000_96.4.361.7","doi-asserted-by":"crossref","DOI":"10.1186\/s12974-022-02450-w","article-title":"CSF GFAP levels in double seronegative neuromyelitis optica spectrum disorder: no evidence of astrocyte damage","volume":"19","author":"Hyun","year":"2022","journal-title":"J Neuroinflammation"},{"key":"2025032404000925000_96.4.361.8","doi-asserted-by":"publisher","DOI":"10.1007\/s13760-021-01712-3"},{"key":"2025032404000925000_96.4.361.9","doi-asserted-by":"publisher","DOI":"10.1016\/s1474-4422(22)00431-8"},{"key":"2025032404000925000_96.4.361.10","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2023.103465"},{"key":"2025032404000925000_96.4.361.11","doi-asserted-by":"publisher","DOI":"10.1177\/1352458506070775"},{"key":"2025032404000925000_96.4.361.12","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2020.00339"},{"key":"2025032404000925000_96.4.361.13","first-page":"38","article-title":"Redefining Acute Relapses in Multiple Sclerosis: implications for Phase 3 Clinical Trials and Treatment Algorithms","volume":"14","author":"Avasarala","year":"2017","journal-title":"Innov Clin Neurosci"},{"key":"2025032404000925000_96.4.361.14","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21145021","article-title":"Differential Effects of MS Therapeutics on B Cells-Implications for Their Use and Failure in AQP4-Positive NMOSD Patients","volume":"21","author":"Traub","year":"2020","journal-title":"Int J Mol Sci"},{"key":"2025032404000925000_96.4.361.15","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2017-315603"},{"key":"2025032404000925000_96.4.361.16","doi-asserted-by":"publisher","DOI":"10.1177\/13524585221111057"},{"key":"2025032404000925000_96.4.361.17","doi-asserted-by":"publisher","DOI":"10.1177\/13524585231199819"},{"key":"2025032404000925000_96.4.361.18","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-023-11634-0"},{"key":"2025032404000925000_96.4.361.19","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2019.101868"},{"key":"2025032404000925000_96.4.361.20","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2020.102522"},{"key":"2025032404000925000_96.4.361.21","doi-asserted-by":"publisher","DOI":"10.1177\/1352458516685416"},{"key":"2025032404000925000_96.4.361.22","doi-asserted-by":"publisher","DOI":"10.1002\/ana.26623"},{"key":"2025032404000925000_96.4.361.23","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2018.12.011"},{"key":"2025032404000925000_96.4.361.24","doi-asserted-by":"publisher","DOI":"10.1177\/1352458513515085"},{"key":"2025032404000925000_96.4.361.25","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2023.103499"},{"key":"2025032404000925000_96.4.361.26","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.25438","article-title":"Analysis of Pregnancy-Related Attacks in Neuromyelitis Optica Spectrum Disorder: a Systematic Review and Meta-Analysis","volume":"5","author":"Wang","year":"2022","journal-title":"JAMA Netw Open"},{"key":"2025032404000925000_96.4.361.27","first-page":"e2089","article-title":"Racial differences in neuromyelitis optica spectrum disorder","volume":"91","author":"Kim","year":"2018","journal-title":"Neurol (ECronicon)"},{"key":"2025032404000925000_96.4.361.28","doi-asserted-by":"publisher","DOI":"10.1016\/s1474-4422(20)30066-1"},{"key":"2025032404000925000_96.4.361.29","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2013.5699"},{"key":"2025032404000925000_96.4.361.30","doi-asserted-by":"publisher","DOI":"10.1177\/1352458515587752"},{"key":"2025032404000925000_96.4.361.31","doi-asserted-by":"publisher","DOI":"10.1177\/1352458517730131"},{"key":"2025032404000925000_96.4.361.32","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2021.660741","article-title":"Eculizumab in the Treatment of Aquaporin-4 Seronegative Neuromyelitis Optica Spectrum Disorder: a Case Report","volume":"12","author":"Digala","year":"2021","journal-title":"Front Neurol"},{"key":"2025032404000925000_96.4.361.33","doi-asserted-by":"publisher","DOI":"10.1007\/S00415-017-8590-0"},{"key":"2025032404000925000_96.4.361.34","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2021.103356"},{"key":"2025032404000925000_96.4.361.35","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1901747"},{"key":"2025032404000925000_96.4.361.36","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(20)30078-8"},{"key":"2025032404000925000_96.4.361.37","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(20)30070-3"},{"key":"2025032404000925000_96.4.361.38","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2019.01028","article-title":"AQP4 Antibody Assay Sensitivity Comparison in the Era of the 2015 Diagnostic Criteria for NMOSD","volume":"10","author":"Prain","year":"2019","journal-title":"Front Neurol"},{"key":"2025032404000925000_96.4.361.39","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-023-11910-z"},{"key":"2025032404000925000_96.4.361.40","doi-asserted-by":"publisher","DOI":"10.1002\/ana.26858"},{"key":"2025032404000925000_96.4.361.41","doi-asserted-by":"crossref","DOI":"10.1177\/20406223211024366","article-title":"Rituximab versus mitoxantrone: comparing effectiveness and safety in advanced relapsing multiple sclerosis","volume":"12","author":"Zrzavy","year":"2021","journal-title":"Ther Adv Chronic Dis"}],"container-title":["Journal of Neurology, Neurosurgery &amp; Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jnnp-2024-334090","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,24]],"date-time":"2025-03-24T11:09:14Z","timestamp":1742814554000},"score":1,"resource":{"primary":{"URL":"https:\/\/jnnp.bmj.com\/lookup\/doi\/10.1136\/jnnp-2024-334090"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,4]]},"references-count":41,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,3,24]]},"published-print":{"date-parts":[[2025,4]]}},"alternative-id":["10.1136\/jnnp-2024-334090"],"URL":"https:\/\/doi.org\/10.1136\/jnnp-2024-334090","relation":{},"ISSN":["0022-3050","1468-330X"],"issn-type":[{"value":"0022-3050","type":"print"},{"value":"1468-330X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,4]]}}}